Jiangxi Synergy Pharmaceutical (SHE:300636) said it received a drug registration certificate from South Korea's Ministry of Food and Drug Safety (MFDS) for its empagliflozin active pharmaceutical ingredient (API), used in treating type 2 diabetes, according to a Wednesday filing with the Shenzhen Bourse.
This approval grants the company market access in South Korea, supporting its international expansion. The certification was issued on Feb. 18.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.